WO 2018/184964 A1). Given the clinical success and unprecedented efficacy of PD-1/PD-L1 checkpoint inhibitors, there remains a major medical need to further improve response rates and duration in patients with pre-existing T cell immunity. Recent reports demonstrate that PD-1 antibodies target two …
